Successful treatment using asfotase alfa for delayed healing of a metatarsal stress fracture in an adolescent girl with hypophosphatasia
Open Access
- 25 April 2026
- journal article
- Published by Springer Nature in Osteoporosis International
- Vol. 37 (5) , 1337-1342
Abstract
Hypophosphatasia (HPP) is a rare metabolic bone disorder that can present with a wide spectrum of skeletal and extraskeletal signs and symptoms. Biochemically, HPP is characterized by a decreased activity of the tissue nonspecific alkaline phosphatase (TNSALP) and subsequent accumulation of inorganic pyrophosphate (PPi). Fractures in patients with HPP can show delayed healing or even progress to nonunion. In pediatric patients, fractures can be particularly debilitating, as children usually engage in high levels of physical activity. The 16-year-old girl, carrying a pathogenic variant in the ALPL gene, presented 17 weeks (4 months) after the initial diagnosis of a fracture at the base of the fifth metatarsal (MT-V). The patient was still symptomatic, and magnetic resonance imaging and cone beam computed tomography (CBCT) showed no radiological signs of healing despite immobilization. Given the prolonged absence of fracture consolidation, TNSALP enzyme replacement therapy with asfotase alfa (AA) was initiated and dosed according to body weight, in line with approved pediatric regimens. Thirteen weeks after initiation of AA, CBCT demonstrated full radiological consolidation. Furthermore, bone mineral density (BMD) in the fracture gap increased by 36%, returning to the average BMD level of the MT-V. Here we present, to the best of our knowledge, the first pediatric case in which treatment with AA supported healing of a delayed union stress fracture in the context of clinically diagnosed and genetically supported HPP. Our findings support considering AA initiation in pediatric patients diagnosed with HPP who present delayed fracture healing despite standard conservative management.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (517063424)
- Universitätsklinikum Hamburg-Eppendorf (UKE)
This publication has 20 references indexed in Scilit:
- Medical Management of Hypophosphatasia: Review of Data on Asfotase AlfaCurrent Osteoporosis Reports, 2025
- Pyridoxine challenge reflects pediatric hypophosphatasia severity and thereby examines tissue-nonspecific alkaline phosphatase's role in vitamin B6 metabolismBone, 2024
- Bone healing and reactivation of remodeling under asfotase alfa therapy in adult patients with pediatric-onset hypophosphatasiaBone, 2021
- Recovery of bone mineralization and quality during asfotase alfa treatment in an adult patient with infantile-onset hypophosphatasiaBone, 2019
- Outcome of Teriparatide Treatment on Fracture Healing Complications and Symptomatic Bone Marrow Edema in Four Adult Patients With HypophosphatasiaJBMR Plus, 2019
- Hypophosphatasia: Canadian update on diagnosis and managementOsteoporosis International, 2019
- Fracture Healing in Two Adult Patients With Hypophosphatasia After Asfotase Alfa TherapyJBMR Plus, 2018
- Clinical, radiographic and biochemical characteristics of adult hypophosphatasiaOsteoporosis International, 2017
- Alkaline Phosphatase and HypophosphatasiaCalcified Tissue International, 2015
- Skeletal mineralization defects in adult hypophosphatasia—a clinical and histological analysisOsteoporosis International, 2011